Myovant Sciences (NYSE:MYOV) issued its earnings results on Tuesday. The company reported ($0.79) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.07), Fidelity Earnings reports.
MYOV stock traded down $0.22 during midday trading on Thursday, reaching $5.88. 19,051 shares of the company were exchanged, compared to its average volume of 480,512. The company has a debt-to-equity ratio of 1.24, a current ratio of 3.42 and a quick ratio of 3.42. The business has a 50-day moving average price of $5.16 and a two-hundred day moving average price of $8.57. Myovant Sciences has a one year low of $4.14 and a one year high of $26.02. The firm has a market capitalization of $544.89 million, a price-to-earnings ratio of -1.44 and a beta of 0.91.
A number of research firms have commented on MYOV. Leerink Swann began coverage on shares of Myovant Sciences in a research report on Monday, August 19th. They set an “outperform” rating and a $26.00 price objective for the company. Zacks Investment Research cut shares of Myovant Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 9th. Goldman Sachs Group set a $18.00 price objective on shares of Myovant Sciences and gave the stock a “buy” rating in a research report on Friday, October 25th. ValuEngine raised shares of Myovant Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Svb Leerink began coverage on shares of Myovant Sciences in a research report on Monday, August 19th. They set an “outperform” rating and a $26.00 price objective for the company. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $21.89.
About Myovant Sciences
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Further Reading: Quantitative Easing
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.